No negative interaction [26]
As a triple incretin receptor agonist, it: Activates GLP-1 receptors , reducing appetite, slowing gastric emptying, and improving insulin secretion Activates GIP receptors , enhancing insulin response and potentially supporting fat metabolism Activates glucagon receptors , increasing energy expenditure and hepatic glucose output Whilst glucagon receptor activation increases hepatic glucose output, the net glycaemic effect of retatrutide is mitigated by the concurrent GLP-1 and GIP activity, resulting in overall improvements in glycaemic control in trial participants
It has minimal direct impact on estrogen, progesterone, cortisol, or prolactin, which is a significant advantage for women
Great for wellness enthusiasts who are concerned with their daily wellness routine
To our knowledge, there have only been three published studies
Regulatory status As of June 2026, tesamorelin is FDA-approved only for HIV-associated lipodystrophy (EGRIFTA WR / EGRIFTA SV)
